Hierarchical clustering of synergy scores for each set of drug‐cell line combinations grouped responses to gefitinib and erlotinib combinations for each HNSCC model, demonstrating that common combinatorial effects were observed with multiple means of EGFR inhibition (Figure 1B). Here, EGFR is linked to head and neck squamous cell carcinoma.